



F'24 Q4 Financial Results



Forward-Looking Statements

In this news release, statements that are not reported financial results or other historic information are "forward-looking statements." These forward-looking statements relate to, among other things, the Company's future financial position, business strategy, targets, projected sales, costs, income, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations.

The use of words such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "should," "project," "plan" or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements by their nature address matters that are, to different degrees, uncertain and are subject to risks, assumptions, and other factors, some of which are beyond Brady's control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For Brady, uncertainties arise from: increased cost of raw materials and labor as well as raw material shortages and supply chain disruptions; decreased demand for our products; our ability to compete effectively or to successfully execute our strategy; our ability to develop technologically advanced products that meet customer demands; Brady's ability to identify, integrate, and grow acquired companies, and to manage contingent liabilities from divested businesses; difficulties in protecting our websites, networks and systems against security breaches; risks associated with the loss of key employees; extensive regulations by U.S. and non-U.S. governmental and self-regulatory entities; global climate change and environmental regulations; litigation, including product liability claims; foreign currency fluctuations; potential write-offs of goodwill and other intangible assets; differing interests of voting and non-voting shareholders and changes in the regulatory and business environment around dual-class voting structures; changes in tax legislation and tax rates; numerous other matters of national, regional and global scale, including major public health crises and government responses thereto and those of a political, economic, business, competitive, and regulatory nature contained from time to time in Brady's U.S. Securities and Exchange Commission filings, including, but not limited to, those factors listed in the "Risk Factors" section within Item 1A of Part I of Brady's Form 10-K for the year ended July 31, 2024.

These uncertainties may cause Brady's actual future results to be materially different than those expressed in its forward-looking statements. Brady does not undertake to update its forward-looking statements except as required by law.




Q4 F'24 Highlights

Improved GPM	GPM of 51.6% compared to 50.8% in Q4 of F'23.Healthy gross profit margins indicative of Brady's high value-add.
Record GAAP & Non-GAAP EPS	 GAAP EPS of \$1.15 was up 15.0% over Q4 of last year. Diluted EPS Excluding Certain Items* increased 14.4% to \$1.19 in Q4 of F'24 compared to \$1.04 in Q4 of F'23.
Regional Results	 Americas & Asia segment profit increased 6.7%. Europe & Australia segment profit increased 4.6%.

Full-Year F'24 Highlights

Record GAAP & Non-GAAP EPS	 GAAP EPS was up 16.0% in F'24 to an all-time high of \$4.07. Diluted EPS Excluding Certain Items* was up 15.9% to an all-time high of \$4.22.
Returned \$117.3M to our Shareholders	 Purchased 1.3M shares in F'24 (approx. 3% of diluted shares). Paid dividends of \$45.1M and announced our 39th consecutive year of dividend increases.
F'25 EPS Guidance	 F'25 GAAP EPS guidance of \$4.15 - \$4.45 (increase of 2.0% to 9.3% over F'24). F'25 Diluted EPS Excluding Certain Items* guidance of \$4.40 - \$4.70 (increase of 4.2% to 11.4% over F'24).
	\$4.70 (increase of 4.3% to 11.4% over F'24).

Sales Overview




Q4 F'24 SALES:

- Total sales decreased 0.7%.
- Organic sales increased 1.6%.
 - Americas & Asia Organic sales increased 3.4%.
 - Europe & Australia Organic sales decreased 1.8%.
- ► Foreign currency translation decreased sales 0.8%.
- Divestitures decreased sales 1.5%.

Q4 F'24 SALES COMMENTARY:

- Organic sales were up 2.3% in the Americas with growth in all major product lines.
- Asia organic sales were up 12.3% with growth in all countries offsetting a decline in organic sales in China.
- Organic sales were down 2.1% in Europe primarily due to a decline in product identification.
- Australia organic sales were up 0.4%.

Gross Profit Margin




Q4 F'24 - GROSS PROFIT MARGIN:

- ► Gross profit margin of 51.6% compared to 50.8% in Q4 of F'23.
- Organic sales growth from higher gross profit margin products and reduced input costs resulted in increased gross profit margin in Q4 of F'24.
- ▶ Inflation continues, but we are experiencing a reduced rate of inflation in most geographies.



SG&A Expense




Q4 F'24 - SG&A EXPENSE:

- ➤ SG&A expense was 27.2% of sales compared to 28.2% of sales in the same quarter last year. Excluding non-GAAP* items from both periods, SG&A expense was 26.5% of sales compared to 27.5% of sales in the same quarter last year.
- Inflation continues in certain geographies. We continue to focus on executing sustainable efficiency gains in order to offset cost increases, while making the necessary investments to drive future sales growth.



R&D Expense




Q4 F'24 – R&D EXPENSE:

- ▶ We remain committed to our investments in R&D in order to drive consistent, long-term sales growth.
- We are focused on ensuring that our R&D spend is both efficient and effective.



Income Before Income Taxes





Q4 F'24 – INCOME BEFORE INCOME TAXES:

- ▶ GAAP Income before income taxes was up 6.9% to \$68.2M in Q4 of F'24 compared to \$63.8M in Q4 of F'23.
- ► GAAP Income before income taxes as a percentage of sales improved 150 basis points to 19.9% in Q4 of F'24 compared to 18.4% in Q4 of F'23.
- Excluding non-GAAP* items from both periods, income before income taxes was up 6.6% to \$70.5M in Q4 of F'24 compared to \$66.2M in Q4 of F'23.



Net Income & Diluted EPS






Q4 F'24 - NET INCOME & DILUTED EPS:

- ▶ GAAP Net Income was \$55.5M in Q4 of F'24 compared to \$49.4M in Q4 of F'23 (an increase of 12.3%).
 - Net Income Excluding Certain Items* was \$57.3M in Q4 of F'24 compared to \$51.2M in Q4 of F'23 (an increase of 11.8%).
- ▶ GAAP Diluted EPS was \$1.15 in Q4 of F'24 compared to \$1.00 in Q4 of F'23 (an increase of 15.0%).
 - Diluted EPS Excluding Certain Items* was \$1.19 in Q4 of F'24 compared to \$1.04 in Q4 of F'23 (an increase of 14.4%).



Cash Generation



(millions of USD)	 os. Ended 31, 2024	 os. Ended 31, 2023			 os. Ended 31, 2023
Cash Balance - Beginning of Period	\$ 160.5	\$ 135.0	\$	151.5	\$ 114.1
Cash Flow from Operating Activities	84.0	79.3		255.1	209.1
Capital Expenditures	(10.7)	(6.3)		(79.9)	(19.2)
Dividends	(11.2)	(11.2)		(45.1)	(45.4)
Share Repurchases	-	(45.2)		(72.2)	(75.0)
Proceeds from Sale of Business	-	-		-	8.0
Debt Borrowings / (Repayments)	27.2	(1.1)		41.2	(45.3)
Effect of Exchange Rates on Cash	(2.1)	1.1		(4.9)	3.1
Other	2.4	0.0		4.4	2.1
Cash Balance - End of Period	\$ 250.1	\$ 151.5	\$	250.1	\$ 151.5

CASH FLOWS IN Q4 OF F'24:

Overview:

- Cash flow from operating activities was \$84.0M in Q4 of F'24 vs. \$79.3M in Q4 of F'23. F'24 cash flow from operating activities was up 22.0% to \$255.1M from \$209.1M in F'23.
- ► Free cash flow* was \$73.2M in Q4 of F'24 compared to \$73.0M in Q4 of F'23.


Returning Funds to our Shareholders:

In F'24, we returned a total of \$117.3M to our shareholders in the form of dividends and share buybacks.

- ▶ Dividends Increased our annual dividend for the 39th consecutive year.
- Share Buybacks Repurchased 1.3M shares in F'24 for \$72.2M (average price of \$56.16/share).



Net Cash



STRONG BALANCE SHEET:

- July 31, 2024 cash = \$250.1M.
- July 31, 2024 debt = \$90.9M.
- Balance sheet provides flexibility for future organic and inorganic investments.



F'24 Financial Summary

(millions of USD)		2024	2023	Change
Sales Organic Sales Growth		1,341.4 2.6%	\$ 1,331.9 5.5%	0.7%
Gross Margin % of Sales		687.9 <i>51.3%</i>	657.3 49.4%	4.7%
Research and Development		(67.7)	(61.4)	10.4%
Selling, General and Administrative % of Sales		(376.7) (28.1%)	(370.7) (27.8%)	1.6%
Operating Income		243.4	225.2	8.1%
Other Income (Expense)		4.4	 0.5	
Income Before Income Taxes	\$	247.8	\$ 225.7	9.8%
Net Income	\$	197.2	\$ 174.9	12.8%
Diluted EPS	<u>\$</u>	4.07	\$ 3.51	16.0%
Non-GAAP Measures:				
Net Income Excluding Certain Items*	\$	204.5	\$ 181.5	12.6%
Diluted EPS Excluding Certain Items*	\$	4.22	\$ 3.64	15.9%

Net Cash Position \$ 159.2 \$ 101.8



F'25 Diluted EPS Guidance

GAAP Diluted EPS \$4.15 to \$4.45 (+2.0% to +9.3%)

F'25 Diluted EPS, Excluding Certain Items*

\$4.40 to \$4.70 (+4.3% to +11.4%)


Guidance Assumptions:

- Organic sales growth in the low-single digit percentages.
- ➤ The only difference between GAAP Diluted EPS and Diluted EPS, Excluding Certain Items* guidance is the impact of amortization expense of approximately \$0.25 per share.
- Full-year income tax rate of approximately 20%.
- ► Foreign currency exchange rates as of July 31, 2024.
- Depreciation and amortization expense of \$38M to \$40M.
- Capital expenditures of approximately \$35M.



Americas & Asia

Q4 F'24 vs. Q4 F'23 (millions of						
	Q4 F'24	Q4 F'23	Change			
Sales	\$ 228.5	\$ 227.5	0.4%			
Segment Profit	53.4	50.0	+ 6.7%			
Segment Profit %	23.3%	22.0%	+ 130 bps			



Q4 F'24 SUMMARY:

- Revenues increased 0.4% in Q4 of F'24:
 - Organic growth = + 3.4%.
 - Fx decrease = (0.8%).
 - Divestiture = (2.2%).
- Organic sales grew 2.3% in the Americas, with organic growth in product ID, wire ID and safety and facility ID product lines, partially offset by declines in people ID and healthcare ID product lines.
- Organic sales grew 12.3% in Asia; growth throughout the region more than offset an organic sales decline in China
- Growth in segment profit due to organic sales growth in higher gross margin product lines, which was partially offset by additional investment in sales and research & development resources.


OUTLOOK:

- Organic sales growth in the low-single digit percentages in F'25.
- · Continued growth in segment profit.



Europe & Australia

Q4 F'24 vs. Q4 F'23 (millions of USD) Q4 F'24 Q4 F'23 Change Sales \$ 114.9 \$ 118.4 (3.0%)**Segment Profit** 19.3 18.4 + 4.6% **Segment Profit %** 16.8% 15.6% + 120 bps



Q4 F'24 SUMMARY:

- Revenues decreased 3.0% in Q4 of F'24:
 - Organic decline = (1.8%).
 - Fx decrease = (1.2%).
- Organic sales declined 2.1% in Europe, primarily due to declines in the product ID and safety and facility ID product lines.
- Organic sales grew 0.4% in Australia primarily due to growth in the wire ID and product ID product lines, partially offset by declines in the safety and facility ID and people ID product lines.
- Segment profit increased primarily due to improved gross profit margins resulting from product mix and reductions in freight expenses.

OUTLOOK:

- Organic sales growth in the low-single digit percentages in F'25.
- Continued growth in segment profit.

Investor Relations

Brady Contact:

Ann Thornton
Investor Relations
414-438-6887

Ann_Thornton@bradycorp.com

See our website at www.bradycorp.com/investors









Appendix

GAAP to Non-GAAP Reconciliations

Non-GAAP Reconciliations

GAAP to NON-GAAP MEASURES

(Unaudited; Dollars in Thousands, Except Per Share Amounts)

In accordance with the U.S. Securities and Exchange Commission's Regulation G, the following provides definitions of the non-GAAP measures used in the earnings release and the reconciliation to the most closely related GAAP measure.

Income Before Income Taxes Excluding Certain Items:

Brady is presenting the non-GAAP measure, "Income Before Income Taxes Excluding Certain Items." This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements and supporting footnote disclosures. We do not view these items to be part of our ongoing results. We believe this profit measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Income before income taxes to the non-GAAP measure of Income Before Income Taxes Excluding Certain Items:

	Three months ended July 31,					31,		
	2024 2023		2024			2023		
Income before income taxes (GAAP measure)	\$	68,208	\$	63,818	\$	247,841	\$	225,696
Amortization expense		2,337		2,389		9,421		11,739
Gain on sale of business		-	,	-		-		(3,770)
Income Before Income Taxes Excluding Certain Items (non-GAAP measure)	\$	70,545	\$	66,207	\$	257,262	\$	233,665

Income Tax Expense Excluding Certain Items:

Brady is presenting the non-GAAP measure, "Income Tax Expense Excluding Certain Items." This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements and supporting footnote disclosures. We do not view these items to be part of our ongoing results. We believe this measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Income tax expense to the non-GAAP measure of Income Tax Expense Excluding Certain Items:

	Three months ended July 31,				Year ended July 31,			
		2024		2023		2024		2023
Income tax expense (GAAP measure)	\$	12,752	\$	14,440	\$	50,626	\$	50,839
Amortization expense		540		553		2,182		2,756
Gain on sale of business		-	,			-	,	(1,431)
Income Tax Expense Excluding Certain Items (non-GAAP measure)	\$	13,292	\$	14,993	\$	52,808	\$	52,164

Non-GAAP Reconciliations

GAAP to NON-GAAP MEASURES

(Unaudited; Dollars in Thousands, Except Per Share Amounts)

In accordance with the U.S. Securities and Exchange Commission's Regulation G, the following provides definitions of the non-GAAP measures used in the earnings release and the reconciliation to the most closely related GAAP measure.

Net Income Excluding Certain Items:

Brady is presenting the non-GAAP measure, "Net Income Excluding Certain Items." This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements and supporting footnote disclosures. We do not view these items to be part of our ongoing results. We believe this measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Net income to the non-GAAP measure of Net Income Excluding Certain Items:

	Three months ended July 31,				Year ended July 31,			
	2024 2023			2024		2023		
Net income (GAAP measure)	\$	55,456	\$	49,378	\$	197,215	\$	174,857
Amortization expense		1,797		1,836		7,239		8,983
Gain on sale of business		-		-		-		(2,339)
Net Income Excluding Certain Items (non-GAAP measure)	\$	57,253	\$	51,214	\$	204,454	\$	181,501

Diluted EPS Excluding Certain Items:

Brady is presenting the non-GAAP measure, "Diluted EPS Excluding Certain Items." This is not a calculation based upon GAAP. The amounts included in this non-GAAP measure are derived from amounts included in the Consolidated Financial Statements. We do not view these items to be part of our ongoing results. We believe this measure provides an important perspective of underlying business trends and results and provides a more comparable measure from year to year. The table below provides a reconciliation of the GAAP measure of Net income per Class A Nonvoting Common Share to the non-GAAP measure of Diluted EPS Excluding Certain Items (Note that certain amounts will not foot due to rounding):

	Three months ended July 31,				Year ended July 31,		
	 2024		2023		2024		2023
Net income per Class A Nonvoting Common Share (GAAP measure)	\$ 1.15	\$	1.00	\$	4.07	\$	3.51
Amortization expense	0.04		0.04		0.15		0.18
Gain on sale of business	-		-		-		(0.05)
Diluted EPS Excluding Certain Items (non-GAAP measure)	\$ 1.19	\$	1.04	\$	4.22	\$	3.64

Diluted EPS Excluding Certain Items Guidance:	Fiscal 2025 Expectations				
		Low	High		
Earnings per diluted Class A Common Share (GAAP measure)	\$	4.15	\$	4.45	
Amortization expense		0.25		0.25	
Diluted EPS Excluding Certain Items (non-GAAP measure)	\$	4.40	\$	4.70	